Core Viewpoint - Rakovina Therapeutics Inc. is undergoing significant corporate updates, including leadership changes, debt restructuring, and financing initiatives to strengthen governance and enhance capital markets execution [1]. Debt Restructuring - The maturity date of the 12.0% convertible debentures, totaling $1,454,000, has been extended from January 28, 2026, to March 11, 2026, with consent from holders representing at least 66 2/3% of the outstanding principal [2][3]. - The company plans to restructure the outstanding 2023 Debentures, offering holders the option to convert their debentures into new Replacement Debentures or settle through a shares-for-debt conversion at $0.12 per share [4][5]. - An agreement in principle has been reached with an existing investor for an additional $1.0 million investment through a private placement of unsecured convertible debentures [7]. Financing Initiatives - The company proposes a concurrent private placement of up to 5,000,000 common shares at $0.12 per share, aiming for additional gross proceeds of up to $500,000 [9]. - The proceeds from the private placements will be used for near-term working capital to support ongoing corporate activities and strategic initiatives [10]. Leadership Changes - Kim Oishi has been appointed as the new Chief Executive Officer and will also join the Board of Directors, bringing extensive experience in public company leadership and capital markets strategy [11][12]. - Frank Holler has been appointed as an independent director, contributing significant expertise in life sciences and governance [16][18][21]. - Jeffrey Bacha will continue as the non-executive Chair of the Board, ensuring continuity and strategic oversight [13][15]. Board Composition - Dr. Dennis Brown has stepped down from the Board but will continue as Chair of the Scientific Advisory Committee, while Al DeLucrezia has also stepped down but will remain as an advisor [23][24]. - The Board's recent changes are aimed at enhancing governance and supporting the company's strategic initiatives in oncology [25][26]. Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments that target the DNA damage response, utilizing advanced computational chemistry and AI-enabled drug discovery platforms [27].

Core Viewpoint - Bunker Hill Mining Corp. has amended its unsecured promissory note with Teck Resources Limited, increasing the principal amount from US$3.4 million to US$4.4 million to secure short-term funding until private placements close [1] Company Overview - Bunker Hill Mining Corp. is focused on revitalizing a historic mining asset in northern Idaho's Coeur d'Alene mining district, specifically targeting zinc, lead, and silver deposits [2] - The company aims to maximize shareholder value while responsibly developing its mineral-rich asset using modern exploration techniques and sustainable practices [2] Financial Arrangement - The amended promissory note bears an interest rate of 12% per annum, with interest capitalized and added to the principal monthly [1] - The note is available in multiple advances at Teck's discretion and is payable in cash on demand [1] - No bonus securities will be issued to Teck in connection with the promissory note, nor is it convertible into the company's securities [1]